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Targeting the epidermal growth factor receptor pathway in pancreatic cancer seems to be an attractive therapeutic approach. This
study assessed the efficacy of cetuximab plus the combination of gemcitabine/oxaliplatin in metastatic pancreatic cancer. Eligible
subjects had histological or cytological diagnosis of metastatic pancreatic adenocarcinoma. The primary end point was response
according to RECIST. Patients received cetuximab 400mgm
 2 at first infusion followed by weekly 250mgm
 2 combined with
gemcitabine 1000mgm
 2 as a 100min infusion on day 1 and oxaliplatin 100mgm
 2 as a 2-h infusion on day 2 every 2 weeks.
Between January 2005 and August 2006, a total of 64 patients (22 women (34%), 42 men (66%); median age 64 years (range 31–
78)) were enrolled at seven study centres. On October 2007, a total of 17 patients were alive. Sixty-two patients were evaluable for
baseline and 61 for assessment of response to treatment in an intention-to-treat analysis. Six patients had an incomplete drug
combination within the first cycle of the treatment plan (n¼4 hypersensitivity reactions to the first cetuximab infusion, n¼2 refused
to continue therapy). Reported grade 3/4 toxicities (% of patients) were leukopaenia 15%, anaemia 8%, thrombocytopaenia 10%,
diarrhoea 7%, nausea 18%, infection 18% and allergy 7%. Cetuximab-attributable skin reactions occurred as follows: grade 0: 20%,
grade 1: 41%, grade 2: 30% and grade 3: 10%. The intention-to-treat analysis of 61 evaluable patients showed an overall response rate
of 33%, including 1 (2%) complete and 19 (31%) partial remissions. There were 31% patients with stable and 36% with progressive
disease or discontinuation of the therapy before re-staging. The presence of a grade 2 or higher skin rash was associated with a higher
likelihood of achieving objective response. Median time to progression was 118 days, with a median overall survival of 213 days. A
clinical benefit response was noted in 24 of the evaluable 61 patients (39%). The addition of cetuximab to the combination of
gemcitabine and oxaliplatin is well tolerated but does not increase response or survival in patients with metastatic pancreatic cancer.
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Pancreatic cancer is the second leading neoplasia of the gastro-
intestinal tract. Only 4% of patients with adenocarcinoma of the
pancreas will be alive 5 years after diagnosis (Jemal et al, 2004).
Until now, weekly gemcitabine is accepted as the standard
palliative chemotherapy for advanced pancreatic cancer, with
median survival of 6 months but associated with a clinical benefit
for example, improvement of pain, weight and performance status
(Burris et al, 1997).
Louvet et al (2002) showed that gemcitabine combined with
oxaliplatin was well tolerated and resulted in a promising response
rate (30.2% for metastatic and 31% for locally advanced disease).
Median progression-free survival (PFS) and overall survival (OS)
were 5.3 and 9.2 months, respectively.
With respect to molecular biology, the epidermal growth factor
receptor (EGFR) has shown to play an important role in the
carcinogenesis of pancreatic cancer (Yamanaka et al, 1993;
Fja ¨llskog et al, 2003). Therefore, targeting the EGFR pathway
seems to be an attractive therapeutic approach. In advanced
pancreatic cancer, Xiong et al (2004) showed that cetuximab in
combination with gemcitabine resulted in an improvement
in response (12.2% partial response (PR), 63.4% stable disease
(SD)), with a median time to progression of 3.8 months and a
median survival of 7.1 months.
On the basis of these data, we assessed the activity of the
combination of gemcitabine with oxaliplatin plus cetuximab
in patients with advanced pancreatic cancer. As outcome of
patients with locally advanced and metastatic pancreatic cancer
is different (Louvet et al, 2002) and most trials combined
both groups of patients so far, only patients with metastatic
disease were included. The objectives of the trial were to
determine the response rate (according to RECIST criteria), time
to progression, survival, clinical benefit response and safety
profile.
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Patients
Patients with histologically or cytologically proven metastatic
(non-regional lymph nodes or distant metastasis) adenocarcinoma
of the pancreas (stage IVb), who had received no previous
chemotherapy, were included in this study. Evidence of EGFR
expression was not necessary for eligibility.
Other eligibility criteria included Karnofsky performance scale
X70%, minimum age of 18 years, at least 6 months since the
completion of any adjuvant therapy, at least 4 weeks since the
completion of any radiation therapy (measurable tumour mass
has to be outside the radiation field) and adequate organ function,
as indicated by a white blood cell count of X3000/ml, haemoglobin
level of X9gdl
 1, platelet count of X100000/ml, alkaline
phosphatase level and serum transaminase level of p5 times the
upper limit of normal (ULN), total bilirubin level of p2 times ULN
and creatinine level of p1.5mgdl
 1. Before treatment, all patients
provided written informed consent according to each institutional
standard. The treatment protocol was approved by local ethics
committees.
Treatment
Patients received cetuximab at an initial dose of 400mgm
 2
followed by weekly doses of 250mgm
 2. Patients were then
observed for 30min for signs of anaphylaxis or other infusion-
related reactions (IRRs). If a patient had an IRR, the infusion time
was doubled from standard time, and this increase was maintained
for subsequent infusions. If a patient had a grade-3 skin toxicity,
the subsequent dose of cetuximab was delayed for up to
2 consecutive weeks, with no change in dose level. If toxicity
resolved to grade 2 or less within 2 weeks, treatment resumed. If a
patient had a second or third occurrence of a grade-3 skin toxicity,
cetuximab was again delayed for up to 2 weeks, with dose
decreases to 200 and 150mgm
 2, respectively.
Sixty minutes after the cetuximab dose, gemcitabine was
administered at a dose of 1000mgm
 2 over a 100min infusion
on day 1 and oxaliplatin at a dose of 100mgm
 2 as a 2-h infusion
on day 2 every 2 weeks.
Dose modifications of gemcitabine and oxaliplatin were
based on absolute neutrophil counts (ANCs) and platelet counts.
Doses were decreased by 25% if the ANC nadir was between
500 10
6 cells per l and 999 10
6 cells per l or the platelet
count nadir was between 50 10
6 cells per l and 99 10
6 cells
per l, and drugs were withheld if the ANC nadir was less than
500 10
6 cells per l or the platelet count nadir less than 50 10
6
cells per l. Missed doses of gemcitabine and oxaliplatin were not
administered and both drugs were restarted when the platelet
count had risen to 100 10
6 cells per l or above and ANC to
1000 10
6 cells per l or more. Gemcitabine and oxaliplatin were
not withheld if the cetuximab infusion was suspended because
of skin toxicity.
During the entire treatment antiemetics (anti-5HT3, steroids)
were given. Furthermore, patients received full supportive care.
Study evaluations
Evaluations before and during the treatment consisted of a
complete medical history and physical examination, assessment
of Karnofsky performance status and laboratory studies, including
haematological and biochemical profiles, computed tomography
or magnetic resonance imaging of the abdomen and chest or
other body areas with disease involvement. Imaging studies were
performed before every fourth cycle and at follow-up visit (unless
the patient discontinued for disease progression) to assess tumour
response.
Clinical benefit was evaluated according to the definition of
Rothenberg et al (1996).
Patients were followed up until death.
Response criteria and toxicity
Tumour response was evaluated and graded using RECIST criteria
(Therasse et al, 2000). Toxicity was categorised using the National
Cancer Institute Common Toxicity Criteria (version 2.0). All
patients who received the study treatment were included in the
analysis of toxicity in an intention-to-treat analysis.
Statistical design
The primary end point was objective response (OR), defined as the
proportion of patients whose best response was either PR or
complete response (CR) in the intent-to-treat population. Second-
ary end points included disease control rate (defined as the
proportion of patients whose best response was CR, PR or SD),
PFS and OS. OS was defined as the time from the beginning of
chemotherapy to death. PFS was defined as the time from the
beginning of chemotherapy to disease progression or death,
whichever occurred first. The event-related end points were
estimated by the Kaplan–Meier method. An exact version of
the w
2 test for trend was applied to assess the association between
skin rash and response.
The sample size was calculated according to a two-stage optimal
design by Simon (1989). On the basis of the findings by Louvet
et al (2002) on the gemcitabine/oxaliplatin combination, an
observed OR of less than 20% was considered as futile, whereas,
in contrast, the experimental combination regimen would be
regarded as a very promising candidate for further evaluation, if an
OR of 40% could be achieved. This resulted in a total sample size
of 54 evaluable patients, with an interim analysis after 19 patients,
allowing to stop futility. Statistical analysis was performed using
the SPlus software (Insightful Corp., Seattle, WA, USA).
RESULTS
Enrollment and patient characteristics
Between January 2005 and September 2006, a total of 64 patients
were enrolled in the study.
Eighteen patients were enrolled at the co-ordinator site of
Regensburg, 14 in Celle, 8 in Halle, 7 in Freiburg, 6 in Augsburg,
6 in Munich (Bogenhausen) and 5 in Frankfurt.
Baseline characteristics of the evaluable patient population
(n¼62) are shown in Table 1.
Table 1 Baseline characteristics
Characteristic
Patients (n) 62
Age, years (median, range) 64.5 (31–78)
Male/female 41/21
Performance status (n)
90–100 33 (63%)
80 13 (25%)
70 6 (12%)
Distant metastasis (n)
Lymph nodes (abdominal/pelvic) 8 (13%)
Liver 58 (93%)
Lung 8 (13%)
Other 22 (35%)
Adjuvant treatment (before start of trial), n 1 (2%)
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to treatment in an intention-to-treat analysis; one patient refused
to take part in the study after giving consent for participation.
One patient could not be treated within the study due to a rapid
deterioration of performance status, and in one patient, no
documentation was available. The study flowchart is shown in
Figure 1.
Six of evaluable patients had an incomplete drug combination
within the first cycle of the treatment plan (n¼4 hypersensitivity
reactions to the first cetuximab infusion, n¼2 refused to continue
therapy).
A total of 499 cycles of chemotherapy were administered in the
study. Patients received a median number of seven cycles (range
1–43). Treatment delays occurred in 27% of all cycles, mainly
(47%) due to organisational reasons (patients’ wish) and only in
12% because of haematological toxicity. In 21%, chemotherapy
doses had to be reduced mainly due to peripheral polyneuropathy
(39%) and haematological toxicity (9%).
Toxicity
The combination of cetuximab with gemcitabine and oxaliplatin
was generally well tolerated. Reported grade 3/4 toxicities (% of
patients) were leukopaenia 15%, anaemia 8%, thrombocytopaenia
10%, diarrhoea 7%, nausea 18%, infection 18% and allergy 7%.
Cetuximab-attributable skin reactions occurred as follows: grade 0:
20%, grade 1: 41%, grade 2: 30% and grade 3: 10%. Clinically
relevant toxicity is summarised in Table 2.
Efficacy
Overall median follow-up time was 154 days (range 15–786).
Table 3 shows responses. One patient (2%) had a CR and 19
patients (31%) a partial remission, with an overall response rate
of 33%. There were 31% patients with stable and 36% with
progressive disease or missing restaging due to early dropout.
Median time to progression was 118 days, with a median OS of 213
days. Figures 2 and 3 show the OS and PFS curves. Forty-seven
patients died. A clinical benefit response was noted in 24 out of
61 patients (39%).
Table 4 shows a rash versus response analysis. The severity of
skin rash was associated with a higher likelihood of achieving
tumour response (P¼0.0031).
In all, 29 out of 61 (47%) patients received second-line therapy,
mainly a fluorouracil-based chemotherapy.
DISCUSSION
Until now, gemcitabine has been widely accepted as a standard
treatment in patients with advanced pancreatic cancer although
Discontinued intervention  (n=7) 
    Give reasons 
refused allocated intervention: 2 
hypersensitivity reactions: 4 
rapid tumor progression: 1 
Lost to follow-up  (n=2) 
   Give reasons 
hypersensitivity reactions: 1 
rapid tumor progression: 1
Allocated to intervention 
(n=61) 
Received allocated intervention 
(n=54) 
Did not receive allocated intervention 
(n=7)
Analyzed for baseline (n=62) 
Analyzed for toxicity  (n=61) 
Excluded from analysis  (n=3) 
Not meeting inclusion criteria: 1 
Refused to participate: 1 
No data available: 1
Allocation 
Analysis 
Follow-up 
Enrolment n=64 
Is it randomised? 
No! 
Figure 1 Flowchart of patients.
Table 2 Treatment-related grade3/4 toxicities
Toxicity NCI grade 3 NCI grade 4
Anaemia 2 (3%) 3 (5%)
Leukopaenia 9 (15%) —
Thrombocytopaenia 6 (10%) —
Nausea 11 (18%) —
Vomiting 4 (7%) 1 (2%)
Diarrhoea 4 (7%) —
Infection 7 (11%) 4 (7%)
Allergy 3 (5%) 1 (2%)
Skin toxicity 6 (10%) —
Table 3 Response to treatment (intention to treat)
N¼61
Complete response, n (%) 1 (2%)
Partial response, n (%) 19 (31%)
Stable disease, n (%) 19 (31%)
Progressive disease, n (%) 10 (16%)
No restaging/early dropout, n (%) 12 (20%)
Objective response, n (%) 20 (33%)
Disease control, n (%) 39 (64%)
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Figure 2 Kaplan–Meier plots for progression-free survival.
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two and even three drug regimens (Adler et al, 2007).
In a phase II study of Louvet et al (2002), gemcitabine combined
with oxaliplatin resulted in a high response rate (31%), and median
OS was also promising for patients with metastatic and locally
advanced disease with 8.7 and 11.5 months, respectively. The
results of a following phase III trial confirmed the efficacy and
safety of gemcitabine combined with oxaliplatin but failed to show
a statistically significant advantage in terms of OS compared with
gemcitabine (Louvet et al, 2005). Nevertheless, analogous to the
phase II trial, median survival times were identical in both arms
for locally advanced patients (30% of total population), whereas
for metastatic patients (70% of the total population), the median
survival time was 6.7 months in the gemcitabine arm and 8.5
months in the gemcitabine/oxaliplatin arm.
Recently, data of a pooled analysis of Heinemann et al (2007)
showed that in patients with good performance status, the
combination of gemcitabine with a platinum analogue, such as
oxaliplatin or cisplatin, significantly improves PFS and OS as
compared with single-agent gemcitabine in advanced pancreatic
cancer.
Therefore, considering the promising results of biological agents
(Xiong et al, 2004), we thought that the addition of cetuximab
to the combination of gemcitabine and oxaliplatin would be
consequently the next step for evaluation in patients with
advanced pancreatic cancer. Furthermore, this is the first study
to our knowledge including only patients with metastatic
pancreatic carcinoma for the evaluation of the activity of a
palliative first-line platin-based chemotherapy protocol.
In our study on 64 patients with metastatic pancreatic
carcinoma, the addition of cetuximab to the combination of
gemcitabine and oxaliplatin was well tolerated and exhibited a
response rate of 33%. The median time to PFS was 3.9 months and
OS was 7.1 months. These findings are not superior to the results
achieved in the earlier studies of gemcitabine and oxaliplatin
alone. Meanwhile, Cascinu et al (2008) reported data of a phase II
trial in which patients with advanced pancreatic cancer were
randomly assigned to treatment with gemcitabine and cisplatin
alone versus gemcitabine and cisplatin plus cetuximab. In all, 61
out of 84 (73%) patients had metastatic disease. Seven out of 40
(17.5%) patients had an OR rate in the cetuximab group and 5 out
of 41 (12.2%) in the non-cetuximab arm. No significant differences
between the groups were noted in the median PFS or in the median
OS. Median PFS was 3.4 months in the cetuximab group and 4.2
months in the non-cetuximab group. Median OS was 7.5 months
and 7.8 months, respectively. Interestingly, toxic effects were not
increased by cetuximab, and at least 33 out of 61 (54%) patients
with metastatic disease received a second-line fluorouracil-based
chemotherapy. The authors concluded from their data that
cetuximab does not add any valuable activity to a combination
of gemcitabine and cisplatin. The findings of Cascinu et al (2008)
are in agreement with those of a phase III study evaluating
cetuximab in combination with gemcitabine compared with
gemcitabine alone in advanced pancreatic cancer, published only
in the abstract form so far (Philip et al, 2007). Seven hundred and
thirty-five patients were randomly enrolled in this latter trial and
78% had metastatic disease. The median survival was 6 months in
the gemcitabine arm and 6.5 months in the gemcitabine plus
cetuximab arm, failing to show a clinically significant advantage of
the addition of cetuximab to gemcitabine.
Interestingly, consistent with the data of Xiong et al (2004), our
results indicate a possible correlation between response and severe
acne rash. Acne rash may therefore play a role as a surrogate
marker of the efficacy of EGFR inhibition.
In conclusion, the addition of cetuximab to a combination of
gemcitabine and oxaliplatin does not result in a prolonged survival
in comparison with earlier studies evaluating gemcitabine and
oxaliplatin alone. Molecular analyses to identify genetic alterations
in pancreatic cancer with a therapeutic potential are warranted for
the future.
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Figure 3 Kaplan–Meier plots for overall survival.
Table 4 Rash and response to treatment
Rash
grade 0
Rash
grade 1
Rash
grade X2
N¼61 12 (20%) 25 (41%) 24 (39%)
Complete response, n (%) — — 1 (4%)
Partial response, n (%) 1 (8%) 6 (24%) 12 (50%)
Stable disease, n (%) 1 (8%) 12 (48%) 6 (25%)
Progressive disease/ No restaging/
early drop out, n (%)
10 (83%) 7 (28%) 5 (21%)
The bold values signify objective response (CR HR) by rash grade. P¼0.0031.
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